Assort Health raised $120 million in a Series C round at a $1.2 billion valuation, announced on June 24, 2026 and led by Menlo Ventures. The round pushes the healthcare AI agent startup past unicorn status and into the front ranks of companies applying voice AI to the least glamorous — and most expensive — part of the healthcare system: getting patients scheduled and processed in the first place.
Here's the full breakdown of the raise, who backed it, and what it says about where AI money is going in healthcare.
What is Assort Health?
Assort Health builds AI agents for the patient journey — voice and messaging bots that handle scheduling, intake, referrals, eligibility verification, medication refills, document processing, and payments for healthcare providers. The system integrates directly with major EHR platforms like Epic and Athena, so it can act inside a practice's existing scheduling and records infrastructure rather than sitting alongside it.
The company was founded by Jon Wang and Jeffery Liu, who serve as co-CEOs. Its underlying model, called Synapse, is trained on a specialty healthcare dataset — reportedly 190 million patient voice interactions, 62,000 care protocols, and 1.6 million decision pathways — which is the kind of domain-specific data moat that's becoming the standard pitch for vertical AI companies trying to differentiate from general-purpose models.
The problem Assort is chasing is unglamorous but massive: understaffed front desks, long hold times, missed appointments, and referral leakage cost health systems billions a year. Automating that layer with an agent that actually understands medical scheduling logic — not just a generic chatbot — is the bet.
The raise: $120M Series C
The headline numbers:
- Amount: $120 million
- Round: Series C
- Valuation: $1.2 billion (post-money)
- Announced: June 24, 2026
- Lead investor: Menlo Ventures
- Total raised to date: more than $222 million
Going from total prior funding of roughly $100 million to a $1.2 billion valuation in this round is a steep step-up, and it puts Assort in the same tier as the better-known clinical-documentation and revenue-cycle AI companies that have raised at billion-dollar-plus valuations over the past two years — except Assort's wedge is patient access rather than clinician-facing documentation.
Who invested in Assort Health?
The Series C was led by Menlo Ventures, a firm that has been active across the healthcare AI and enterprise AI agent space. Participants included:
- Lightspeed Venture Partners
- Felicis
- First Round Capital
- Chemistry
- Tau Ventures
- Quiet Capital
- Joe Montana (the former NFL quarterback, investing through his venture activity)
The mix of top-tier multi-stage funds alongside early-stage specialists and a high-profile individual angel is fairly typical of a healthcare AI round at this size — it signals both institutional conviction and enough buzz to attract non-traditional backers.
What the money is for
Assort Health says the capital will fund its move from serving multi-site outpatient practices into full enterprise health systems — a much larger and more complex customer segment, with longer sales cycles, deeper EHR integration requirements, and more demanding compliance and security bars. That's a meaningful shift in go-to-market difficulty, and the funding is explicitly earmarked for the commercial and engineering lift that requires.
The company has pointed to 20x revenue growth over the prior 15 months as the traction underpinning the raise, along with results from a health system partner (John Muir Health) showing a 115% increase in administrative labor capacity and a 5% absolute lift in net appointment volume after deploying the platform. Those are the kinds of hard operational metrics — not just usage numbers — that make a compelling case to enterprise health system buyers who are naturally risk-averse about handing scheduling to an AI agent.
Why it matters
Assort Health's round is a useful read on where healthcare AI investment is concentrating in 2026:
- Patient access is now a proven AI category. Scheduling and intake used to be seen as too fragmented and compliance-heavy for AI agents to touch. A $1.2 billion valuation says investors now see it as a large, addressable, and technically tractable market.
- Voice AI is moving from novelty to infrastructure. The pitch isn't "AI that can talk to patients" anymore — it's an agent platform wired into Epic and Athena that health systems can actually deploy at scale.
- Vertical data moats are the differentiator. Assort's emphasis on its Synapse dataset — millions of real patient voice interactions and care protocols — reflects a broader pattern of healthcare AI startups betting that proprietary, domain-specific training data is what separates a defensible company from a thin wrapper on a foundation model.
For a fuller picture of how this raise stacks up against the rest of 2026's largest AI funding rounds, see Wortins' rundown of the biggest AI funding rounds of 2026.
Following AI funding? Wortins tracks the biggest raises, valuations, and acquisitions daily in the AI Funding Tracker.